FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3049757680> ?p ?o ?g. }

• W3049757680 endingPage "1139" @default.
• W3049757680 startingPage "1135" @default.
• W3049757680 abstract "Currently, there is no molecular-targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u-HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real-world study, we aimed to investigate the therapeutic effect and safety of sorafenib (SOR) in patients with u-HCC after progression on treatment with LEN.A total of 13 patients with u-HCC (12 males and 1 female), who were treated with SOR after progression on LEN, were enrolled in this retrospective study. Therapeutic efficacy was evaluated via contrast-enhanced computerized tomography at 8 weeks after the initiation of SOR therapy according to modified response evaluation criteria in solid tumors (mRECIST) and RECIST. According to mRECIST, the objective response rate (ORR) and disease control rate (DCR) were 15.3% (2/13) and 69.2% (9/13), respectively. According to RECIST, the ORR and DCR were 0% (0/13) and 69.2% (9/13), respectively. The median progression-free survival was 4.1 months. The median albumin-bilirubin scores did not deteriorate significantly at 4, 6, and 8 weeks after initiation of SOR, compared with the scores at the baseline. The most frequent grade 1 or 2 adverse events (AEs) were palmar-plantar erythrodysesthesia, fatigue, diarrhea, and hypertension. There was no incidence of grade 3 AEs.Treatment with SOR may be effective for u-HCC after failure on LEN and may not worsen the liver reserve." @default.
• W3049757680 created "2020-08-21" @default.
• W3049757680 creator A5004862363 @default.
• W3049757680 creator A5014108501 @default.
• W3049757680 creator A5021158752 @default.
• W3049757680 creator A5030298726 @default.
• W3049757680 creator A5037589463 @default.
• W3049757680 creator A5037709270 @default.
• W3049757680 creator A5055984304 @default.
• W3049757680 creator A5067573679 @default.
• W3049757680 creator A5084113589 @default.
• W3049757680 creator A5090795865 @default.
• W3049757680 date "2020-08-15" @default.
• W3049757680 modified "2023-10-10" @default.
• W3049757680 title "Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma" @default.
• W3049757680 cites W1937746457 @default.
• W3049757680 cites W1971837077 @default.
• W3049757680 cites W1987732545 @default.
• W3049757680 cites W1994193851 @default.
• W3049757680 cites W2019294726 @default.
• W3049757680 cites W2019607817 @default.
• W3049757680 cites W2076668534 @default.
• W3049757680 cites W2079586464 @default.
• W3049757680 cites W2110643890 @default.
• W3049757680 cites W2119190881 @default.
• W3049757680 cites W2140765540 @default.
• W3049757680 cites W2147172608 @default.
• W3049757680 cites W2161558746 @default.
• W3049757680 cites W2176831251 @default.
• W3049757680 cites W2236745112 @default.
• W3049757680 cites W2277004004 @default.
• W3049757680 cites W2560499218 @default.
• W3049757680 cites W2591717879 @default.
• W3049757680 cites W2787358630 @default.
• W3049757680 cites W2796067155 @default.
• W3049757680 cites W2809889937 @default.
• W3049757680 cites W2888056309 @default.
• W3049757680 cites W2905083507 @default.
• W3049757680 cites W2908573150 @default.
• W3049757680 cites W2942632018 @default.
• W3049757680 cites W2973111363 @default.
• W3049757680 cites W2989005830 @default.
• W3049757680 cites W3015053767 @default.
• W3049757680 cites W3038811185 @default.
• W3049757680 cites W776120597 @default.
• W3049757680 cites W2591655368 @default.
• W3049757680 doi "https://doi.org/10.1002/jgh3.12408" @default.
• W3049757680 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7731817" @default.
• W3049757680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33319048" @default.
• W3049757680 hasPublicationYear "2020" @default.
• W3049757680 type Work @default.
• W3049757680 sameAs 3049757680 @default.
• W3049757680 citedByCount "10" @default.
• W3049757680 countsByYear W30497576802021 @default.
• W3049757680 countsByYear W30497576802022 @default.
• W3049757680 crossrefType "journal-article" @default.
• W3049757680 hasAuthorship W3049757680A5004862363 @default.
• W3049757680 hasAuthorship W3049757680A5014108501 @default.
• W3049757680 hasAuthorship W3049757680A5021158752 @default.
• W3049757680 hasAuthorship W3049757680A5030298726 @default.
• W3049757680 hasAuthorship W3049757680A5037589463 @default.
• W3049757680 hasAuthorship W3049757680A5037709270 @default.
• W3049757680 hasAuthorship W3049757680A5055984304 @default.
• W3049757680 hasAuthorship W3049757680A5067573679 @default.
• W3049757680 hasAuthorship W3049757680A5084113589 @default.
• W3049757680 hasAuthorship W3049757680A5090795865 @default.
• W3049757680 hasBestOaLocation W30497576801 @default.
• W3049757680 hasConcept C126322002 @default.
• W3049757680 hasConcept C143998085 @default.
• W3049757680 hasConcept C197934379 @default.
• W3049757680 hasConcept C2776264508 @default.
• W3049757680 hasConcept C2776694085 @default.
• W3049757680 hasConcept C2778019345 @default.
• W3049757680 hasConcept C2778695046 @default.
• W3049757680 hasConcept C2778822529 @default.
• W3049757680 hasConcept C2779984678 @default.
• W3049757680 hasConcept C71924100 @default.
• W3049757680 hasConcept C90924648 @default.
• W3049757680 hasConceptScore W3049757680C126322002 @default.
• W3049757680 hasConceptScore W3049757680C143998085 @default.
• W3049757680 hasConceptScore W3049757680C197934379 @default.
• W3049757680 hasConceptScore W3049757680C2776264508 @default.
• W3049757680 hasConceptScore W3049757680C2776694085 @default.
• W3049757680 hasConceptScore W3049757680C2778019345 @default.
• W3049757680 hasConceptScore W3049757680C2778695046 @default.
• W3049757680 hasConceptScore W3049757680C2778822529 @default.
• W3049757680 hasConceptScore W3049757680C2779984678 @default.
• W3049757680 hasConceptScore W3049757680C71924100 @default.
• W3049757680 hasConceptScore W3049757680C90924648 @default.
• W3049757680 hasIssue "6" @default.
• W3049757680 hasLocation W30497576801 @default.
• W3049757680 hasLocation W30497576802 @default.
• W3049757680 hasOpenAccess W3049757680 @default.
• W3049757680 hasPrimaryLocation W30497576801 @default.
• W3049757680 hasRelatedWork W1873011119 @default.
• W3049757680 hasRelatedWork W2024938637 @default.
• W3049757680 hasRelatedWork W2370121646 @default.
• W3049757680 hasRelatedWork W2466156289 @default.

• next